UKINETS2017 Poster Presentations (1) (40 abstracts)
1-Year survival rates for neuroendocrine tumour patients in England
Tracey Genus 1, , Catherine Bouvier 1 , Kwok Wong 2 , Rajaventhan Srirajaskanthan 3 , Brian Rous 4, , Denis Talbot 6, , Juan Valle 8, , Mohid Khan 10 , Neil Pearce 11 , Mona Elshafie 12 , Nicholas Reed 13 , Tu Vinh Luong 14 , Alia Munir 15 & John Ramage 3
1NET Patient Foundation, Leamington Spa, UK; 2National Cancer Registration and Analysis Service Public Health England, Birmingham, UK; 3Kings College Hospital, London, UK; 4Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; 5National Cancer Registration Service, Cambridge, UK; 6University of Oxford, Oxford, UK; 7Oxford University Hospitals NHS Foundation Trust, Oxford, UK; 8University of Manchester, Manchester, UK; 9The Christie NHS Foundation Trust, Manchester, UK; 10University Hospital of Wales, Cardiff, UK; 11University Hospital Southampton NHS Foundation Trust, Southampton, UK; 12University Hospital Birmingham NHS Foundation Trust, Birmingham, UK; 13Beatson Oncology Centre, Gartnavel General Hospital, Glasgow, UK; 14Royal Free London NHS Foundation Trust, London, UK; 15Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Introduction: Accurate survival data for patients with neuroendocrine tumours (NETs) across the UK has been difficult to capture. Individual centres often report good survival rates, however, national data has not previously been available.
Materials and methods: NET patient survival was calculated for England using the Public Health England (PHE) National Cancer Registration and Analysis Service (NCRAS) dataset which captures tumour stage using TNM staging. Grade was based on dysplasia and morphology. The Kaplan-Meier survival method was used to analyse overall death in 12,755 patients diagnosed with a NET between 2013 and 2015.
Results: The 1-year overall survival was 75% for NETs (95% CI, 74.5–76.1), 72% in males vs 79% in females (P < .001). Survival by age group was as follows: 0–55 years 90% (95% CI, 89.2–91.2); 56–65 80% (95% CI, 78.3–81.4); 66–75 71% (95% CI, 70.0–72.9); >75 60% (95% CI, 57.9–61.5) (with P < .001 for comparisons between all age groups). Survival decreased with increasing grade (1/2 and 3) and stage (1, 2, 3, and 4 respectively):
Colorectal (n=2712):: Grade 1/2 (excluding Mixed adenoneuroendocrine carcinoma (MANEC)): 99% (97.6–99.4); 97% (93.9–98.3); 99% (95.4–99.7); 80% (72.9–86.2)
Grade 3 (excluding MANEC): 89% (70.4–96.4); 90% (72.9–96.8); 67% (56.3–76.2); 22% (16.3–27.9)
MANEC: 98% (85.8–99.7); 97% (92.3–99.2); 85% (74.4–91.8); 60% (45.2–72.6)
Overall (including unknown stage): 88% (86.5–88.9)
Lung (n=2,460, excluding *small and large cell lung cancer):
Grade 1/2: 98% (97.2–99.1); 98% (93.7–99.6); 93% (82.9–97.4); 69% (59.1–76.8)
Grade 3: 93% (89.4–95.6); 81% (71.4–88.2); 63% (55.0–70.7); 26% (22.5–30.0)
Overall: 74% (72.7–76.2) in comparison, *SCLC (n=97,239) 42% (42.2–42.8)
Pancreas (n=1,207):
Grade 1/2: 97% (92.7–98.7); 95% (88.8–97.6); NK; 85% (79.7–89.6)
Grade 3: 87% (68.3–94.8); 87% (58.6–96.7); 56% (30.5–74.7); 42% (35.9–48.9)
Overall: 81% (78.3–82.8)
Small bowel (n=1,688):
Grade 1/2: 98% (90.8–99.4); 96% (89.7–98.5); 96% (93.6–97.3); 88% (84.3–90.7)
Grade 3: NK; NK; 83% (60.1–93.1); 72% (60.5–80.5)
Overall: 90% (88.6–91.5)
Conclusion: The survival results show that tumour grade has the potential to be a good prognostic indicator for all types of NET. This is the first large series regarding MANEC demonstrating poor outcomes.
Keywords: Neuroendocrine cancer; survival; grade; stage; age
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more